China s HiFiBiO Therapeutics bags $75m Series D led by Mirae Asset Financial Group dealstreetasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dealstreetasia.com Daily Mail and Mail on Sunday newspapers.
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
News provided by
Share this article
Share this article
1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the phase III China clinical trial (PaTHway China Trial) of TransCon PTH Solution for Injection (TransCon™ parathyroid hormone).
2. PaTHway China Trial is designed to assess the potential of TransCon™ PTH as a hormone replacement therapy, and the aim is to enable patients to have serum calcium (sCa) within the normal range and independence from usual care.
Oregon Investment Council committed a combined $100 million to Sherpa Healthcare Partners Fund II, an early stage to growth stage private equity fund managed by Sherpa Healthcare Partners, and a sidecar, Rex Kim, CIO at the Oregon state treasury, reported at a council meeting. Separately, the…
Published: May 11, 2021 By Heather McKenzie
Appia co-founder and chief executive officer, JJ Kang/Photo Courtesy of Appia Bio
Backed by $52 million in Series A financing led by 8VC and named after a feat of engineering in ancient Rome, Appia Bio jumped into the cell therapy fray this morning with a promising scalable technology platform.
“The company is named after the Aqua Appia, which is the first Roman aqueduct. It was kind of a feat of engineering and it brought water to a lot more people, and that thematically connects well. We want to engineer these cells and provide a broader reach for cell therapy through allogeneic off-the-shelf,” said Appia co-founder and chief executive officer, JJ Kang, Ph.D.
Appia Bio Launches With $52 Million Series A Financing and Establishes Scientific Advisory Board
Proceeds will be used to progress stem cell derived CAR-engineered invariant natural killer T cells (CAR-iNKT) to the clinic in hematological and solid tumor indications
News provided by
Share this article
Share this article
LOS ANGELES, May 11, 2021 /PRNewswire/ Appia Bio, Inc., an early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, today announced its launch from stealth backed by $52 million Series A financing led by 8VC. Other investors included Two Sigma Ventures, among others, and participation from seed investors Sherpa Healthcare Partners and Freeflow Ventures.